$6.32
1.10% yesterday
Nasdaq, Jun 12, 10:00 pm CET
ISIN
US92539P1012
Symbol
VERV

Verve Therapeutics Inc Stock price

$6.32
+1.97 45.29% 1M
+0.09 1.44% 6M
+0.68 12.06% YTD
+0.73 13.06% 1Y
-25.60 80.20% 5Y
-25.60 80.20% 10Y
-25.60 80.20% 20Y
Nasdaq, Closing price Thu, Jun 12 2025
-0.07 1.10%
ISIN
US92539P1012
Symbol
VERV
Sector
Industry

Key metrics

Market capitalization $563.39m
Enterprise Value $66.31m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 1.11
P/S ratio (TTM) P/S ratio 9.45
P/B ratio (TTM) P/B ratio 1.19
Revenue growth (TTM) Revenue growth 271.40%
Revenue (TTM) Revenue $59.61m
EBIT (operating result TTM) EBIT $-208.45m
Free Cash Flow (TTM) Free Cash Flow $-146.98m
Cash position $497.08m
EPS (TTM) EPS $-2.03
P/E forward negative
P/S forward 13.18
EV/Sales forward 1.55
Short interest 26.37%
Show more

Is Verve Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,845 stocks worldwide.

Verve Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

10 Analysts have issued a Verve Therapeutics Inc forecast:

9x Buy
90%
1x Hold
10%

Analyst Opinions

10 Analysts have issued a Verve Therapeutics Inc forecast:

Buy
90%
Hold
10%

Financial data from Verve Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Mar '25
+/-
%
60 60
271% 271%
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 58 58
12% 12%
97%
- Research and Development Expense 210 210
13% 13%
353%
-202 -202
7% 7%
-338%
- Depreciation and Amortization 6.84 6.84
15% 15%
11%
EBIT (Operating Income) EBIT -208 -208
6% 6%
-350%
Net Profit -181 -181
8% 8%
-304%

In millions USD.

Don't miss a Thing! We will send you all news about Verve Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Verve Therapeutics Inc Stock News

Neutral
GlobeNewsWire
11 days ago
BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that on May 30, 2025, the company granted equity awards to four new employees, pursuant to the company's 2024 Inducement Stock Incentive Plan, as an inducement material to each new employee entering into employment with th...
Neutral
GlobeNewsWire
16 days ago
BOSTON , May 28, 2025 (GLOBE NEWSWIRE) -- Verve Therapeutics, a clinical-stage company developing a new class of genetic medicines for cardiovascular disease, today announced that management will participate in fireside chats during the following investor conferences:
Positive
Seeking Alpha
24 days ago
Here's the next batch of weird science stocks that have market darling potential. I'm tracking five meme-worthy, deep science sectors: brain-computer interfaces, CRISPR/gene editing, organoids, programmable cell therapy, and room-temperature superconductors. Monitor each sector's stocks poised to soar if a major tech player announces a breakthrough.
More Verve Therapeutics Inc News

Company Profile

Verve Therapeutics, Inc. is a genetic medicines company engaged in the development of a new approach to the care of cardiovascular disease. It aims to transform treatment from chronic management to single-course gene editing medicines. Its goal is to disrupt the chronic care model for CVD by providing a new therapeutic approach with single-course in vivo gene editing treatments focused on addressing the root causes of this highly prevalent and life-threatening disease. The company was founded by Sekar Kathiresan, Kiran Musunuru, Keith J. Joung, Issi Rozen, Sekar Kathiresan, and Burt A. Adelman in 2018 and is headquartered in Cambridge, MA.

Head office United States
CEO Sekar Kathiresan
Employees 255
Founded 2018
Website www.vervetx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today